Researchers found no difference in the risk of bleeding events or arterial thromboembolism events between any of the three groups for the first 90 days of use.
Medical experts are concerned about the new-generation anticoagulants, as they do not have a reversal agent, in the event of a serious or catastrophic bleeding, which can result in deadly results.